The global pulmonary arterial hypertension market size is expected to reach USD 9.8 billion by 2027, according to a new report by Grand View Research, Inc., registering a CAGR of 5.6% over the forecast period. Increasing prevalence rates of pulmonary arterial hypertension (PAH) and government support for the development of orphan drugs drive the market growth.
The cases of PAH are rising in the range of 100,000 to 200,000 per year. However, in the past few years, the occurrence of PAH has been increasing due to risk factors such as alcohol/tobacco consumption, HIV, sedentary lifestyle, smoking, and other idiopathic conditions. Moreover, the geriatric population is more prone to PAH and associated diseases owing to reduced immune function. According to the National Council on Aging (NCOA), about 80 percent of the population aged 65 and above have at least one chronic condition such as high cholesterol, diabetes, heart or kidney disease, or chronic obstructive pulmonary disease.
Government initiatives such as the Rare Disease Act 2002 and The Orphan Drug Act (ODA) 1983, are also anticipated to support the market for treatment drugs for PAH. These acts play a significant role in promoting the ethical usage and distribution of orphan drugs. The development of orphan drugs is promoted by the National Organization of Rare Disorders.
Robust drug pipeline and new product combinations awaiting approval or launch are anticipated to increase the PAH market competitiveness over the forecast period. In September 2019, Acceleron Pharma, a leading biopharmaceutical company, received FDA orphan drug designation for sotatercept for the treatment of pulmonary arterial hypertension.
To request a sample copy or view summary of this report, click the link below:
Further key findings from the report suggest:
Prostacyclin and its analogs for treating PAH are projected to show lucrative growth over the forecast period. The sales of these drugs are anticipated to increase due to the growing use of oral prostacyclin agents
North America dominated the PAH market with a share of over 55.0% in 2019. This is attributed to the well-established infrastructure for the development and distribution of high-quality therapies and the availability of reimbursement for PAH therapies
Asia Pacific is estimated to register the highest CAGR of more than 6.0% over the forecast period due to its huge population base, rapid economic development, and improving healthcare system. Moreover, the high burden of diseases such as HIV in the region contribute to the development of PAH
The major players in the pulmonary arterial hypertension market that offer treatment solutions for PAH include GlaxoSmithKline plc; Johnson & Johnson Services, Inc. (Actelion Pharmaceuticals, Ltd.); United Therapeutics Corporation; Pfizer, Inc.; and Gilead Sciences, Inc. The market is consolidated and competitive in nature. The players enjoy the benefit of high entry barriers to other firms due to high price interdependency
Grand View Research has segmented the global pulmonary arterial hypertension market on the basis of drug class and region:
Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2016 - 2027)
Prostacyclin and Prostacyclin Analogs
Soluble Guanylate Cyclase (SGC) Stimulators
Endothelin Receptor Antagonists (ERA)
Phosphodiesterase 5 (PDE-5)
Pulmonary Arterial Hypertension Regional Outlook (Revenue, USD Million, 2016 - 2027)
Middle East and Africa (MEA)
This report has a service guarantee. We stand by our report quality.
Your transaction & personal information is safe and secure.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
Avail customized purchase options to meet your research needs:
"The quality of research they have done for us has been excellent..."